Drug intelligence / Profile preview

OPL-0301

Development stage: Discontinued
Lead developer: Valo Health
Modality: Small Molecules
Administration: Oral

Overview

OPL-0301 is a biased sphingosine 1-phosphate receptor 1 (S1P₁) agonist developed by Valo Health for the treatment of cardiovascular conditions, specifically post-myocardial infarction left ventricular dysfunction. The drug aims to reduce infarct size and improve heart function following a heart attack by targeting vascular and endothelial dysfunction and inflammation through S1P₁ receptor agonism. It was investigated as an oral small molecule therapy but development has been discontinued[2][3][7].

Other names: OPL-0301OPL0301OPL 0301

Targets

EDG1 (Sphingosine-1-phosphate receptors)

Beyond the preview

Go deeper on OPL-0301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPL-0301.

Explore the full profile